Raymond G. Cavalcante
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raymond G. Cavalcante has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Maureen A. Sartor
Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, USA
77 shared publications - Bailey F. Garb
Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, Michigan
72 shared publications - Elysia Chou
Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, Michigan
72 shared publications - Laura S. Rozek
Georgetown University Medical Center, Department of Oncology, Washington, DC, USA
72 shared publications - Leanne E. Henry
University of Michigan, Ann Arbor, MI
72 shared publications - Nisha J. D'SIlva
Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, USA
72 shared publications
Latest Publications
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Data from CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/β-Catenin Signaling to Inhibit EZH2-Driven EMT
Metaplastic breast carcinomas (mBrCA) are a highly aggressive subtype of triple-negative breast cancer with histologic evidence of epithelial-to-mesenchymal transition and aberrant differentiation. Inactivation of the tumor suppressor gene cellular communication network factor 6 (CCN6; also known as Wnt1-induced secreted protein 3) is a feature of mBrCAs, and mice with conditional inactivation of Ccn6 in mammary epithelium (Ccn6-KO) develop spindle mBrCAs with epithelial-to-mesenchymal transition. Elucidation of the precise mechanistic details of how CCN6 acts as a tumor suppressor in mBrCA could help identify improved treatment strategies. In this study, we showed that CCN6 interacts with the Wnt receptor FZD8 and coreceptor LRP6 on mBrCA cells to antagonize Wnt-induced activation of β-catenin/TCF-mediated transcription. The histone methyltransferase EZH2 was identified as a β-catenin/TCF transcriptional target in Ccn6-KO mBrCA cells. Inhibiting Wnt/β-catenin/TCF signaling in Ccn6-KO mBrCA cells led to reduced EZH2 expression, decreased histone H3 lysine 27 trimethylation, and deregulation of specific target genes. Pharmacologic inhibition of EZH2 reduced growth and metastasis of Ccn6-KO mBrCA mammary tumors in vivo. Low CCN6 is significantly associated with activated β-catenin and high EZH2 in human spindle mBrCAs compared with other subtypes. Collectively, these findings establish CCN6 as a key negative regulator of a β-catenin/TCF/EZH2 axis and highlight the inhibition of β-catenin or EZH2 as a potential therapeutic approach for patients with spindle mBrCAs. Significance: CCN6 deficiency drives metaplastic breast carcinoma growth and metastasis by increasing Wnt/β-catenin activation to upregulate EZH2, identifying EZH2 inhibition as a mechanistically guided treatment strategy for this deadly form of breast cancer.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/β-Catenin Signaling to Inhibit EZH2-Driven EMT
Metaplastic breast carcinomas (mBrCA) are a highly aggressive subtype of triple-negative breast cancer with histologic evidence of epithelial-to-mesenchymal transition and aberrant differentiation. Inactivation of the tumor suppressor gene cellular communication network factor 6 (CCN6; also known as Wnt1-induced secreted protein 3) is a feature of mBrCAs, and mice with conditional inactivation of Ccn6 in mammary epithelium (Ccn6-KO) develop spindle mBrCAs with epithelial-to-mesenchymal transition. Elucidation of the precise mechanistic details of how CCN6 acts as a tumor suppressor in mBrCA could help identify improved treatment strategies. In this study, we showed that CCN6 interacts with the Wnt receptor FZD8 and coreceptor LRP6 on mBrCA cells to antagonize Wnt-induced activation of β-catenin/TCF-mediated transcription. The histone methyltransferase EZH2 was identified as a β-catenin/TCF transcriptional target in Ccn6-KO mBrCA cells. Inhibiting Wnt/β-catenin/TCF signaling in Ccn6-KO mBrCA cells led to reduced EZH2 expression, decreased histone H3 lysine 27 trimethylation, and deregulation of specific target genes. Pharmacologic inhibition of EZH2 reduced growth and metastasis of Ccn6-KO mBrCA mammary tumors in vivo. Low CCN6 is significantly associated with activated β-catenin and high EZH2 in human spindle mBrCAs compared with other subtypes. Collectively, these findings establish CCN6 as a key negative regulator of a β-catenin/TCF/EZH2 axis and highlight the inhibition of β-catenin or EZH2 as a potential therapeutic approach for patients with spindle mBrCAs. Significance: CCN6 deficiency drives metaplastic breast carcinoma growth and metastasis by increasing Wnt/β-catenin activation to upregulate EZH2, identifying EZH2 inhibition as a mechanistically guided treatment strategy for this deadly form of breast cancer.
- 18 July 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (19) , 3235-3249
CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/β-Catenin Signaling to Inhibit EZH2-Driven EMT
Metaplastic breast carcinomas (mBrCA) are a highly aggressive subtype of triple-negative breast cancer with histologic evidence of epithelial-to-mesenchymal transition and aberrant differentiation. Inactivation of the tumor suppressor gene cellular communication network factor 6 (CCN6; also known as Wnt1-induced secreted protein 3) is a feature of mBrCAs, and mice with conditional inactivation of Ccn6 in mammary epithelium (Ccn6-KO) develop spindle mBrCAs with epithelial-to-mesenchymal transition. Elucidation of the precise mechanistic details of how CCN6 acts as a tumor suppressor in mBrCA could help identify improved treatment strategies. In this study, we showed that CCN6 interacts with the Wnt receptor FZD8 and coreceptor LRP6 on mBrCA cells to antagonize Wnt-induced activation of β-catenin/TCF-mediated transcription. The histone methyltransferase EZH2 was identified as a β-catenin/TCF transcriptional target in Ccn6-KO mBrCA cells. Inhibiting Wnt/β-catenin/TCF signaling in Ccn6-KO mBrCA cells led to reduced EZH2 expression, decreased histone H3 lysine 27 trimethylation, and deregulation of specific target genes. Pharmacologic inhibition of EZH2 reduced growth and metastasis of Ccn6-KO mBrCA mammary tumors in vivo. Low CCN6 is significantly associated with activated β-catenin and high EZH2 in human spindle mBrCAs compared with other subtypes. Collectively, these findings establish CCN6 as a key negative regulator of a β-catenin/TCF/EZH2 axis and highlight the inhibition of β-catenin or EZH2 as a potential therapeutic approach for patients with spindle mBrCAs. Significance: CCN6 deficiency drives metaplastic breast carcinoma growth and metastasis by increasing Wnt/β-catenin activation to upregulate EZH2, identifying EZH2 inhibition as a mechanistically guided treatment strategy for this deadly form of breast cancer.
- 18 July 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (19) , 3235-3249
CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/β-Catenin Signaling to Inhibit EZH2-Driven EMT
Metaplastic breast carcinomas (mBrCA) are a highly aggressive subtype of triple-negative breast cancer with histologic evidence of epithelial-to-mesenchymal transition and aberrant differentiation. Inactivation of the tumor suppressor gene cellular communication network factor 6 (CCN6; also known as Wnt1-induced secreted protein 3) is a feature of mBrCAs, and mice with conditional inactivation of Ccn6 in mammary epithelium (Ccn6-KO) develop spindle mBrCAs with epithelial-to-mesenchymal transition. Elucidation of the precise mechanistic details of how CCN6 acts as a tumor suppressor in mBrCA could help identify improved treatment strategies. In this study, we showed that CCN6 interacts with the Wnt receptor FZD8 and coreceptor LRP6 on mBrCA cells to antagonize Wnt-induced activation of β-catenin/TCF-mediated transcription. The histone methyltransferase EZH2 was identified as a β-catenin/TCF transcriptional target in Ccn6-KO mBrCA cells. Inhibiting Wnt/β-catenin/TCF signaling in Ccn6-KO mBrCA cells led to reduced EZH2 expression, decreased histone H3 lysine 27 trimethylation, and deregulation of specific target genes. Pharmacologic inhibition of EZH2 reduced growth and metastasis of Ccn6-KO mBrCA mammary tumors in vivo. Low CCN6 is significantly associated with activated β-catenin and high EZH2 in human spindle mBrCAs compared with other subtypes. Collectively, these findings establish CCN6 as a key negative regulator of a β-catenin/TCF/EZH2 axis and highlight the inhibition of β-catenin or EZH2 as a potential therapeutic approach for patients with spindle mBrCAs. Significance: CCN6 deficiency drives metaplastic breast carcinoma growth and metastasis by increasing Wnt/β-catenin activation to upregulate EZH2, identifying EZH2 inhibition as a mechanistically guided treatment strategy for this deadly form of breast cancer.
- Open Access
- 30 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 1 from Whole-genome CpG-resolution DNA Methylation Profiling of HNSCC Reveals Distinct Mechanisms of Carcinogenesis for Fine-scale HPV+ Cancer Subtypes
Companion figure showing significance results for main Figure 1D-F and Figure 2A.
- 30 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 1 from Whole-genome CpG-resolution DNA Methylation Profiling of HNSCC Reveals Distinct Mechanisms of Carcinogenesis for Fine-scale HPV+ Cancer Subtypes
Companion figure showing significance results for main Figure 1D-F and Figure 2A.
- Open Access
- 30 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Whole-genome CpG-resolution DNA Methylation Profiling of HNSCC Reveals Distinct Mechanisms of Carcinogenesis for Fine-scale HPV+ Cancer Subtypes
DNA methylation-based gene set enrichment captures gene expression-based pathway-level differences. A, Dotplot for top 40 significant RNA enrichment terms, colored by −log10(P-value) illustrating enrichment results from RNA, DMRs across the whole genome, <5 kb from TSS, exons, and introns. B, Scatter plot for directional RNA and DNA methylation enrichment test results. Right quadrants represent significantly hypermethylated GO terms in IMU; top quadrants represent overexpressed terms in IMU. Red: terms significant with FDR < 0.05 for both methylation and expression. C–F, Specific genes’ visualization from paradigmatic GO terms, top: DNA methylation profile across gene body with 30% gene length flank regions. Gray lines: IMU versus KRT significant DMRs. Orange lines: Significant cis-eQTMs overlapped with DMRs, middle: differential 5hmc peaks in IMU versus KRT, bottom: bar plot for subgroups’ log2cpm expression value with edgeR FDR values. Color: subgroups.
- 30 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Whole-genome CpG-resolution DNA Methylation Profiling of HNSCC Reveals Distinct Mechanisms of Carcinogenesis for Fine-scale HPV+ Cancer Subtypes
DNA methylation-based gene set enrichment captures gene expression-based pathway-level differences. A, Dotplot for top 40 significant RNA enrichment terms, colored by −log10(P-value) illustrating enrichment results from RNA, DMRs across the whole genome, <5 kb from TSS, exons, and introns. B, Scatter plot for directional RNA and DNA methylation enrichment test results. Right quadrants represent significantly hypermethylated GO terms in IMU; top quadrants represent overexpressed terms in IMU. Red: terms significant with FDR < 0.05 for both methylation and expression. C–F, Specific genes’ visualization from paradigmatic GO terms, top: DNA methylation profile across gene body with 30% gene length flank regions. Gray lines: IMU versus KRT significant DMRs. Orange lines: Significant cis-eQTMs overlapped with DMRs, middle: differential 5hmc peaks in IMU versus KRT, bottom: bar plot for subgroups’ log2cpm expression value with edgeR FDR values. Color: subgroups.
- Open Access
- 30 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 2 from Whole-genome CpG-resolution DNA Methylation Profiling of HNSCC Reveals Distinct Mechanisms of Carcinogenesis for Fine-scale HPV+ Cancer Subtypes
Average methylation of tumors and normal epithelial cells at gene body (A), promoter (B), CpG island (C) and repetitive region (D). Samples were grouped by HPVor HPV integration status.
- 30 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 2 from Whole-genome CpG-resolution DNA Methylation Profiling of HNSCC Reveals Distinct Mechanisms of Carcinogenesis for Fine-scale HPV+ Cancer Subtypes
Average methylation of tumors and normal epithelial cells at gene body (A), promoter (B), CpG island (C) and repetitive region (D). Samples were grouped by HPVor HPV integration status.